Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring<i> FGFR2</i> amplifications

  • Satoh, Taroh; 
  • Barthelemy, Philippe; 
  • Nogova, Lucia; 
  • Honda, Kazunori; 
  • Hirano, Hidekazu; 
  • ... Park, Joon Oh; 
  • 외 10명
Citations

WEB OF SCIENCE

17

초록

Background and aims: Aberrant fibroblast growth factor receptor (FGFR)-driven signaling, predominantly arising from FGFR2 amplification, plays a key role in gastric cancer pathogenesis. This open-label, phase 2 study evaluated the efficacy and safety of futibatinib, an irreversible FGFR1-4 inhibitor, in patients with gastric or gastroesophageal junction (GEJ) cancer harboring FGFR2 amplifications. Methods: Patients were treated with futibatinib 20 mg orally once daily in a 28-day cycle. The primary endpoint was objective response rate (ORR) per independent central review. Secondary endpoints included progression- free survival (PFS), overall survival (OS), and safety. Results: Among 28 treated patients, the ORR per independent central review was 17.9%, comprising five patients with a partial response (median duration of response, 3.9 months), and an additional nine patients with stable disease for a disease control rate of 50.0 %. Median PFS per independent central review and median OS were 2.9 and 5.9 months, respectively. The most common treatment-related adverse events (any grade) were hyperphosphatemia (89.3 %), decreased appetite (32.1 %), and increased aspartate aminotransferase (21.4 %). Only one (3.6 %) patient discontinued study treatment due to an adverse event. Futibatinib demonstrated modest antitumor activity with a safety profile consistent with previous reports in patients with gastric or GEJ cancer harboring FGFR2 amplifications, potentially warranting further investigation.

키워드

Futibatinib; TAS-120; Fibroblast growth factor receptor; Fibroblast growth factor receptor 2; FGFR2; Gastric cancer; Gastroesophageal junction; Stomach cancer; FGFR2 AMPLIFICATION; OPEN-LABEL; ADENOCARCINOMA; INHIBITOR
제목
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring<i> FGFR2</i> amplifications
저자
Satoh, Taroh; Barthelemy, Philippe; Nogova, Lucia; Honda, Kazunori; Hirano, Hidekazu; Lee, Keun-Wook; Rha, Sun Young; Ryu, Min-Hee; Park, Joon Oh; Doi, Toshihiko; Ajani, Jaffer; Hangai, Nanae; Kremer, Jill; Mina, Mark; Liu, Mei; Shitara, Kohei
DOI
10.1016/j.ejca.2025.115262
발행일
2025-03-11
유형
Article
저널명
European Journal of Cancer
권
218